Onconetix, Inc. Incremental Common Shares Attributable to Dilutive Effect of Nonvested Shares with Forfeitable Dividends
Onconetix, Inc. (ONCO) reported Incremental Common Shares Attributable to Dilutive Effect of Nonvested Shares with Forfeitable Dividends of 263 shares for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends · last filed 2026-08-13
- Onconetix, Inc. incremental common shares attributable to dilutive effect of nonvested shares with forfeitable dividends for the quarter ending 2026-03-31 was 263.00 shares, a 471.74% increase year-over-year.
- Onconetix, Inc. incremental common shares attributable to dilutive effect of nonvested shares with forfeitable dividends for the quarter ending 2025-03-31 was 46.00 shares, a 98.69% decline year-over-year.
- Onconetix, Inc. incremental common shares attributable to dilutive effect of nonvested shares with forfeitable dividends for the quarter ending 2024-03-31 was 3.52K shares.
- Onconetix, Inc. incremental common shares attributable to dilutive effect of nonvested shares with forfeitable dividends for fiscal 2025 was 1.95K shares, a 825.12% increase from fiscal 2024.
- Onconetix, Inc. incremental common shares attributable to dilutive effect of nonvested shares with forfeitable dividends for fiscal 2024 was 211.00 shares, a 96.71% decline from fiscal 2023.
- Onconetix, Inc. incremental common shares attributable to dilutive effect of nonvested shares with forfeitable dividends for fiscal 2023 was 6.41K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Nonvested Shares with Forfeitable Dividends 3 month | Incremental Common Shares Attributable to Dilutive Effect of Nonvested Shares with Forfeitable Dividends 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Nonvested Shares with Forfeitable Dividends 6 month | Incremental Common Shares Attributable to Dilutive Effect of Nonvested Shares with Forfeitable Dividends 6 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Nonvested Shares with Forfeitable Dividends 9 month | Incremental Common Shares Attributable to Dilutive Effect of Nonvested Shares with Forfeitable Dividends 9 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Nonvested Shares with Forfeitable Dividends 12 month | Incremental Common Shares Attributable to Dilutive Effect of Nonvested Shares with Forfeitable Dividends 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 263.00 shares 10-Q · filed 2026-05-13 | |||||||
| 2025-12-31 | 1.95K shares 10-K · filed 2026-03-13 | |||||||
| 2025-09-30 | 2.59K shares 10-Q · filed 2025-11-13 | |||||||
| 2025-06-30 | 4.00 shares 10-Q · filed 2026-08-13 | 231.00 shares 10-Q · filed 2025-08-14 | ||||||
| 2025-03-31 | 46.00 shares 10-Q · filed 2026-05-13 | 19.63K shares 10-Q · filed 2025-06-12 | ||||||
| 2024-12-31 | 211.00 shares 10-K · filed 2026-03-13 | 17.92K shares 10-K · filed 2025-06-02 | ||||||
| 2024-09-30 | 211.00 shares 10-Q · filed 2025-11-13 | 17.92K shares 10-Q · filed 2024-12-10 | ||||||
| 2024-06-30 | 31.00 shares 10-Q · filed 2025-08-14 | 106.25K shares 10-Q · filed 2024-08-29 | ||||||
| 2024-03-31 | 3.52K shares 10-Q · filed 2025-06-12 | 140.96K shares 10-Q · filed 2024-05-20 | ||||||
| 2023-12-31 | 6.41K shares 10-K · filed 2025-06-02 | |||||||
| 2023-09-30 | 8.60K shares 10-Q · filed 2024-12-10 | |||||||
| 2023-06-30 | 512.94K shares 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |